- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01877759
A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis
Role of Bone Marrow Derived Autologous Stem Cells + Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Liver Cirrhosis
Cirrhosis is caused by sustained liver damage over several years either by alcohol, viral infection (Hepatitis B, C), a toxic substance (for eg. drugs, excess copper or iron in the liver), or by blockage of biliary system such that the liver undergoes progressive scarring that slowly replaces all of normal liver cells.(LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. For this condition of disease the liver transplantation is one of the only effective therapies available ,but due to lack of donors, surgical complications, rejection, and high cost are it's serious problems.
Presently stem cells are used to be a one of the treatment for the same. So our approach is to evaluate the safety and efficacy of mesenchymal stem cell in condition of liver cirrhosis .
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Smita S Bhoyar, B.A.M.S.PGCR
- Phone Number: 9372620569
- Email: drsmitabhoyar@rediff.com
Study Locations
-
-
Maharashtra
-
Pune,, Maharashtra, India, 411009
- Chaitanya Hospital
-
Contact:
- Smita S Bhoyar, BAMS.PGCR
- Phone Number: 9372620569
- Email: drsmitabhoyar@rediffmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- 25 -65 Ages Eligible for Study
- Clinical diagnosis of liver cirrhosis
- Ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required Informed Consent Form (ICF) for the study.
- Expecting lifetime is over three years
- Ready to come all visits
Exclusion Criteria:
- History of life threatening allergic or immune-mediated reaction
- Positive test results for HIV and AIDS complex ,HCV , HbsAg and Syphilis
- Malignancies
- Sepsis
- Vital organs failure
- Pregnant or lactating women
- Subject who has been transplanted recently
- If the investigator or treating physician feels that the Subject with any disease or condition would interfere with the trial or the safety of patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Mesenchymal stem cell
hUMAN MESENCHYMAL STEM CELLS
|
Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in Liver function tests
Time Frame: 6 month
|
1) Improvement of Liver Function tests liver functions( Albumin (ALB), Alanine aminotransferase (ALT), Aspartate Aminotransferase (AST), Prealbumin(PA), total bilirubin (TB), and direct bilirubin (DB) kidney function Blood urea nitrogen (BUN), Urea (UA), and Crea (Cr)),international normalized ratio (INR) in Liver Cirrhosis Patients
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in liver function according to Child-Pugh
Time Frame: 6 MONTH
|
6 MONTH
|
Changes in liver function according to MELD Score
Time Frame: 6 MONTH
|
6 MONTH
|
Improvement in QUALITY OF LIFE SCALE (QOL)
Time Frame: 6 month
|
6 month
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes of any clinical symptoms like abdominal distension, appetite, debilitation
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSCC/BM/2013/LS/01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on Mesenchymal stem cell
-
Mayo ClinicUniversity of Alabama at Birmingham; University of Mississippi Medical CenterCompletedChronic Kidney Disease | Renal Artery Stenosis | Ischemic Nephropathy | Renovascular DiseaseUnited States
-
Children's Hospital of Chongqing Medical UniversityUnknown
-
Mayo ClinicCompletedBronchiolitis Obliterans | Lung Transplant RejectUnited States
-
University of LiegeCompletedHematological MalignanciesBelgium
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical University; Chongqing Maternal and...Withdrawn
-
Celal Bayar UniversityThe Scientific and Technological Research Council of Turkey; Acıbadem LabcellCompletedSkin Diseases | Immune System Diseases | Autoimmune Diseases | UrticariaTurkey
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Children's Hospital of Chongqing Medical UniversityUnknownBronchopulmonary DysplasiaChina
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Samsung Medical CenterPharmicell Co., Ltd.UnknownStroke, IschemicKorea, Republic of